Hyland to acquire OneContent from Allscripts
Hyland, the creator of process management software OneBase, has acquired OneContent from US-based health record technology firm, Allscripts.
OneContent allows access to patient’s records for healthcare staff through electronic solutions.
The software has approximately 300 customers, which Hyland intend to continue to support following the acquisition.
The contract is expected to be finalised in the second quarter of this year.
Hyland plans to enhance the features and functionality of the platform, with a focus on the Allscript Paragon HER system.
The firm also plans to use OneContent to amplify its Hyland Healthcare software – a platform that allows staff to upload, view, and share medical documents through cloud-based technology.
The deal “aligns with Hyland Healthcare’s focus on combining information management and enterprise medical imaging with business process and case management capabilities,” a spokesperson announced.
“Based on Hyland’s experience helping more than 2,000 healthcare organizations manage patient content over the past 16 years, we are well prepared to serve the needs of OneContent customers and eager to help them reach their goal,” commented the President and CEO of Hyland, Bill Priemer.
Skin Analytics wins NHSX award for AI skin cancer tool
An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system.
NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion.
Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making.
In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog.
Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening.
DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.
Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.
Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges.
"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”